Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma

Journal of Clinical Oncology

Volumn 21, Issue 3, 2003, Pages 421-427

  Patt, Yehuda Z ^a   Hassan, Manal M ^a   Lozano, Richard D ^a   Brown, Thomas D ^a   Vauthey, J Nicolas ^a   Curley, Steven A ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; ADJUVANT THERAPY; ADOLESCENT; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS;

EID: 0037315472     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.103     Document Type: Article

References (42)

1. El Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999
2. El Serag HB, Mason AC: Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160:3227-3230, 2000
3. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562, 1999
5. Hassan MM, Hwang LY, Hatten CJ, et al: Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206-1213, 2002
6. Friedman MA: Primary hepatocellular cancer-present results and future prospects. Int J Radiat Oncol Biol Phys 9:1841-1850, 1983
7. Lin DY, Lin SM, Liaw YF: Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S319-S328, 1997
8. Lai CL, Wu PC, Chan GC, et al: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479-483, 1988
9. Melia WM, Johnson PJ, Williams R: Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with Adriamycin. Cancer 5:206-210, 1983
10. Lai CL, Wu PC, Lok AS, et al: Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: A prospective randomised trial. Br J Cancer 60:928-933, 1989
11. Patt YZ, Hoque A, Roh M, et al: Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication. Am J Clin Oncol 22:209-213, 1999
12. Leung TW, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676-1681, 1999
13. Baffis V, Shrier I, Sherker AH, et al: Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 131:696-701, 1999
14. Nishiguchi S, Kuroki T, Nakatani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995
15. Giannini E, Fasoli A, Botta F, et al: Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: A functional study. J Gastroenterol Hepatol 16:399-405, 2001
16. Okuno M, Kojima S, Moriwaki H: Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives. J Gastroenterol Hepatol 16:1329-1335, 2001
17. Marchetti S, Chazal M, Dubreuil A, et al: Impact of thymidine phosphorylase superexpression on fluoropyrimidine activity and on tumour angiogenesis. Br J Cancer 85:439-445, 2001
18. Braybrooke JP, Propper DJ, O'Byrne KJ, et al: Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Br J Cancer 83:219-224, 2000
19. Morita T, Tokue A: Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: Relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol 44:91-96, 1999
20. Wadler S, Horowitz R, Mao X, et al: Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks. Cancer Chemother Pharmacol 38:529-535, 1996
21. Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769-1775, 1989
22. Corfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995
23. Greco FA, Figlin R, York M, et al: Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14:2674-2681, 1996
24. Hughes MJ, Kerr DJ, Cassidy J, et al: A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours. Ann Oncol 7:208-210, 1996
25. Saltz L, Kemeny N, Schwartz G, et al: A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 74:958-961, 1994
26. Altmann HW: Some histological remarks on the fibrolamellar carcinoma of the liver. Pathol Res Pract 186:63-69, 1990
27. Rolfes DB: Fibrolamellar carcinoma of the liver, in Okuda K, Ishak KG (eds): Neoplasms of the Liver. New York, NY, Springer 1987, pp 137-142
28. Stevens WR, Johnson CD, Stephens DH, et al: Fibrolamellar hepatocellular carcinoma: Stage at presentation and results of aggressive surgical management. AJR Am J Roentgenol 164:1153-1158, 1995
29. Hassan M, Patt YZ, Lozano R, et al: Continuous I. V. infusion of 5-fluorouracil (5-FU) and subcutaneous (S. C.) recombinant interferon alpha 2b (rIFNα 2b) is an active regimen in fibrolamellar hepatocellular carcinoma (FLHCC). Proc Am Soc of Clin Oncol, 19, 2000 (abstr 122)
30. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication No. 48. Geneva, 1979
31. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1-10, 1989
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrics 52:203-223, 1965
34. Brown JJ, Naylor MJ, Yagan N: Imaging of hepatic cirrhosis. Radiology 202:1-16, 1997
35. Brown NS, Bicknell R: Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 334:1-8, 1998
36. Ishikawa F, Miyazono K, Hellman U, et al: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557-562, 1989
37. Moghaddam A, Bicknell R: Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31:12141-12146, 1992
38. Miyadera K, Sumizawa T, Haraguchi M, et al: Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55:1687-1690, 1995
39. Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol 3:89-96, 1992
40. Sgonc R, Fuerhapter C, Boeck G, et al: Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Int Arch Allergy Immunol 117:209-214, 1998
41. Dinney CP, Bielenberg DR, Perrotte P, et al: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58:808-814, 1998
42. Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690, 1998